What families and prescribers say
Three composite accounts, written as short narratives rather than pull quotes. Every account below is composite; clinical specifics, geography, and timing have been altered to protect patient privacy.
We do not publish named testimonials. The families who engage us are private, the cases are sensitive, and a pull quote on a website is not the right form for the trust they extend to us. What follows is three composite accounts, each of which is assembled from multiple engagements and written in a single voice. The accounts describe the shape of the work, not the details of any one case.
A family navigating a US-approved cell therapy
Composite account. Details changed to protect patient privacy.
The family in this account is a US-citizen household that had been spending half of each year in a Gulf country for business. A close relative was diagnosed with a relapsed haematologic malignancy, and the specialist named a cell therapy that was approved in the United States but not yet available at the treating centre overseas. The family's first instinct was to fly the patient to a US academic centre; the treating physician, who was an experienced clinician in the destination city, felt strongly that the continuity of care overseas was better for the patient than a disruption to a new US team late in the disease course. The question, practically, was whether the therapy could be sourced and delivered into the treating centre's workflow under a named-patient authorisation, or whether the geography was going to force a harder choice.
The family described the engagement with Reserve Meds as "unusually quiet". The first conversation was on a secure video line the day after the enquiry. The coordinator they were assigned stayed with them from intake to delivery, and the family spoke to the same person every time. When the cold-chain routing had to be re-planned because of a change in the hospital's receiving hours, they were told about it before they thought to ask. When the import file required a second version of a document, it was drafted on our side and sent for the physician's signature, not theirs. The part they mentioned most often afterwards was that, in a period where everything else in their life felt urgent, the procurement question had become boring. That, they said, was the compliment.
A UAE-based prescriber coordinating an ultra-rare paediatric indication
Composite account. Details changed to protect patient privacy.
This prescriber is a consultant paediatrician at a tertiary centre in the United Arab Emirates, working on an ultra-rare metabolic indication for a young child. The US-approved enzyme-replacement therapy was the clearly preferred option on the evidence base, the family had the means and the willingness to pursue a named-patient route, and the centre had a relationship with the ministry of health that made an authorisation realistic. What the prescriber did not have was the bandwidth to assemble the US-side sourcing, the DSCSA documentation, the cold-chain routing, and the ministry submission on top of a full clinic load.
The prescriber's description of the engagement was pragmatic. The pharmacist-in-charge handled every dispensing question physician-to-pharmacist, in writing, which matched the way the prescriber preferred to work. The ministry submission was drafted on our side, with the medical-rationale letter left for the prescriber to edit rather than to write from a blank page. The first shipment arrived with a full dossier that the hospital pharmacy accepted without a back-and-forth, and subsequent cycles have moved on a predictable rhythm. What the prescriber said they valued, specifically, was that we did not ask them to do our work for us. They had a patient to look after, and the named-patient file was ours.
A hospital pharmacy director arranging a single-patient import
Composite account. Details changed to protect patient privacy.
This pharmacy director runs a specialty pharmacy at a large private hospital in a South Asian capital. The case concerned a single adult patient, an advanced autoimmune condition, and a biologic that was approved in the United States and not yet registered locally. The hospital had processed named-patient imports before, and the P&T committee was receptive, but the specific product fell into a limited-distribution network in the United States that was unfamiliar to their previous broker. Reserve Meds was brought in on a recommendation from a peer institution.
The pharmacy director described the engagement as "a clean file". The credentialing was done once, up front, so that subsequent cycles did not require a restart. The DSCSA transaction history was delivered with the first shipment and carried a serial record that the quality office accepted without a second look. The cold-chain packout matched the hospital's receiving SOP. The pharmacovigilance commitment was accepted on our side and the monthly reporting arrived without reminders. When a regulatory authorisation for the indication changed scope mid-year, we flagged it to the pharmacy director before their team had seen the circular, which they noted was the sort of thing they had, in the past, found out about from a supplier's invoice rather than from the supplier. They have since extended the engagement to a second indication.
Reviewed 2026-04-22 by Reserve Meds's AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.